Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).Dieter Koeberle, G. Bodoky, Gyula Demeter et al.|Journal of Clinical Oncology|2014Cited by 5